Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Travera Inc
Stanford University
University of California, Davis
Hoffmann-La Roche
ViroMissile, Inc.
University of Florida
Barbara Ann Karmanos Cancer Institute
University of Nebraska
Guerbet
Fusion Pharmaceuticals Inc.
Eli Lilly and Company
Tanabe Pharma America, Inc.
Massive Bio, Inc.
Circle Pharma
Jonsson Comprehensive Cancer Center
MedSIR
University Health Network, Toronto
Novartis
National Cancer Institute (NCI)
Eli Lilly and Company
Aminex Therapeutics, Inc.
Taproot Health
Travera Inc
Rigshospitalet, Denmark
Novartis
Georgetown University
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center
Xencor, Inc.
Provectus Pharmaceuticals
EMD Serono
Vanderbilt-Ingram Cancer Center
SpeciCare
Novartis
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
AbbVie
SWOG Cancer Research Network
Emory University
Rigshospitalet, Denmark
University of Southern California
Stanford University
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)